Market Trends– category –
-
Zimislecel: Islet Cell Therapy’s Impact on Type 1 Diabetes Distress
Healio USA Overview Zimislecel, a stem cell-derived islet cell therapy from Vertex Pharmaceuticals, reduced HbA1c to below 7% and eliminated severe hypoglycemia in 12 adults with type 1 diabetes over one year. The therapy significantly l... -
iPSC-based Parkinson’s Therapy: Japan’s First Commercialized Cell Treatments
Neurodegenerative Diseases and Brain Aging USA Overview Japan has authorized the world's first two commercial induced pluripotent stem cell (iPSC)-based therapies, including a treatment for Parkinson's Disease. The therapy utilizes allog... -
Graphene Oxide: Boosting Stem Cell Exosome Yield for Wound Healing
BIOENGINEER.ORG South Korea Overview Researchers have developed a method using graphene oxide to turn induced pluripotent stem cell spheroids into high-output exosome factories, nearly doubling production to 2.75 billion particles per mi... -
CAR T-Cell vs Bispecific Antibodies: Relapsed MCL Response Rates
AJMC (The American Journal of Managed Care) USA Overview A systematic review and meta-analysis indicates that CAR T-cell therapy achieves a higher complete response rate (70%) than bispecific antibodies (63%) in patients with relapsed or... -
FDA vs EMA: CGT manufacturing and potency assay requirements
Rhizome AI USA Overview Significant structural differences exist between FDA and EMA manufacturing controls and GMP requirements for Cell and Gene Therapy (CGT) at the IND/CTA stage. The FDA maintains more explicit early-stage requiremen... -
Indian Health Ministry Issues Advisory to States, UTs to Regulate Stem Cell Therapy; Limits Autism Application to Clinical Trials
ETV Bharat India Overview The Indian Ministry of Health and Family Welfare has issued a comprehensive advisory to all states and Union Territories, reinforcing regulations on stem cell therapies following directives from the Supreme Cour... -
BioInformant Report Outlines 2026 iPSC-Derived Cell Therapeutic Pipeline, Highlighting Safety Challenges and Key Developers
BioInformant USA Overview This article provides an overview of a market research report by BioInformant, focusing on the 2026 pipeline for iPSC-derived cell therapeutics. The report analyzes the current state and future challenges, ident... -
CRISPR Therapeutics Anticipates CASGEVY Market Expansion and Key Pipeline Catalysts by Year-End 2026
MarketBeat USA Overview CRISPR Therapeutics expresses strong optimism for the continued market adoption of its approved gene-editing therapy, CASGEVY, and anticipates significant data updates from multiple key pipeline programs by the en...
1